Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

After A Year Of Pelvic Mesh Criticism, US FDA Calls Meeting To Discuss The Beleaguered Products

Executive Summary

Following a number of reports and a major documentary criticizing the use of surgical mesh in transvaginal surgeries, regulators are calling on an expert panel and other stakeholders to provide recommendations on their safety and effectiveness. 

You may also be interested in...



FDA Wants Feedback On How To Properly Label Devices With Risky Materials

The US agency wants stakeholders to chime in on what information should be included in product labels to notify patients about potential side-effects of medical device materials, without being too burdensome for manufacturers.

US Medtech Lobbyists Say They're Not Worried About Political Backlash From 'Implant Files'

The International Consortium of Investigative Journalists started publishing the findings of its "Implant Files" investigation last month, but the two main industry groups in the US have not picked up any significant political backlash resulting from the reporting so far.

FDA Looks To Lead World In Post-Market Device Surveillance With Safety Plan, Investments

US FDA Nov. 20 announced plans for a broad series of updates to its Medical Device Safety Action Plan for the next several months, with the goal that FDA "is consistently first among the world’s regulatory agencies to identify and act upon safety signals related to medical devices.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124412

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel